The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry
As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
El País in English13d
What are the limits in the fight against obesity? Ozempic owner disappoints the market
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Europe markets close slightly lower but notch weekly gain; Burberry up 10% after quarterly report
European equity markets are set to open higher on Friday to cap a positive week for stocks. The U.K.'s FTSE 100 is set to ...
ndtvprofit13d
Don't Pin All Your Hopes On Weight Loss Drugs: Here's Why
Besides diabetes, obesity is a major risk factor for hypertension and heart disease, creating what can only be described as a ...
Seeking Alpha25d
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential
This difference is crucial, because making insulin means biologically reproducing a human hormone ... growth market, but of the two I believe the greatest potential at the moment is in Novo Nordisk.